Trials / Completed
CompletedNCT01302041
A Study to Test if Enzalutamide is Effective and Safe in Prostate Cancer Patients Who Have Never Had Hormone Therapy
A Phase 2, Open-label, Single-arm, Efficacy and Safety Study of Enzalutamide (MDV3100) in Patients With Hormone-naïve Prostate Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Enzalutamide | Oral |
Timeline
- Start date
- 2011-05-06
- Primary completion
- 2012-07-29
- Completion
- 2017-04-27
- First posted
- 2011-02-23
- Last updated
- 2018-10-02
- Results posted
- 2016-04-06
Locations
12 sites across 4 countries: Belgium, Czechia, Denmark, Germany
Source: ClinicalTrials.gov record NCT01302041. Inclusion in this directory is not an endorsement.